Indobufen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Indobufen
Accession Number
DB12545
Type
Small Molecule
Groups
Investigational
Description

Indobufen has been used in trials studying the supportive care and prevention of Atrial Fibrillation.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
6T9949G4LZ
CAS number
63610-08-2
Weight
Average: 295.338
Monoisotopic: 295.120843411
Chemical Formula
C18H17NO3
InChI Key
AYDXAULLCROVIT-UHFFFAOYSA-N
InChI
InChI=1S/C18H17NO3/c1-2-15(18(21)22)12-7-9-14(10-8-12)19-11-13-5-3-4-6-16(13)17(19)20/h3-10,15H,2,11H2,1H3,(H,21,22)
IUPAC Name
2-[4-(1-oxo-2,3-dihydro-1H-isoindol-2-yl)phenyl]butanoic acid
SMILES
CCC(C(O)=O)C1=CC=C(C=C1)N1CC2=CC=CC=C2C1=O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Indobufen is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Indobufen is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Indobufen is combined with 5-androstenedione.Experimental, Illicit
AbciximabIndobufen may increase the anticoagulant activities of Abciximab.Approved
AcebutololIndobufen may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Indobufen.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Indobufen is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolIndobufen may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Indobufen.Approved, Vet Approved
AclarubicinIndobufen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Indobufen.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Indobufen is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Indobufen is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Indobufen is combined with Aldosterone.Experimental, Investigational
AldoxorubicinIndobufen may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level.Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Indobufen is combined with Alendronic acid.Approved
AliskirenIndobufen may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Indobufen is combined with Alminoprofen.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Indobufen is combined with Aloxiprin.Experimental
AlprenololIndobufen may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilAlprostadil may increase the anticoagulant activities of Indobufen.Approved, Investigational
AlteplaseIndobufen may increase the anticoagulant activities of Alteplase.Approved
AmcinonideThe risk or severity of adverse effects can be increased when Indobufen is combined with Amcinonide.Approved
AmikacinIndobufen may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideIndobufen may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Indobufen.Approved
AmrubicinIndobufen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AnagrelideAnagrelide may increase the anticoagulant activities of Indobufen.Approved
AncrodIndobufen may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideAndrographolide may increase the anticoagulant activities of Indobufen.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Indobufen is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Indobufen is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Indobufen is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Indobufen.Investigational
AnistreplaseIndobufen may increase the anticoagulant activities of Anistreplase.Approved
AnnamycinIndobufen may decrease the excretion rate of Annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Indobufen.Approved
Antithrombin III humanIndobufen may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanThe risk or severity of adverse effects can be increased when Indobufen is combined with Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Indobufen is combined with Apocynin.Investigational
ApramycinIndobufen may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Indobufen.Approved, Investigational
AprotininThe therapeutic efficacy of Indobufen can be decreased when used in combination with Aprotinin.Approved, Withdrawn
ArbekacinIndobufen may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinIndobufen may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanIndobufen may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololIndobufen may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
AstaxanthinIndobufen may increase the anticoagulant activities of Astaxanthin.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Indobufen is combined with Atamestane.Investigational
AtenololIndobufen may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Indobufen.Withdrawn
AzelastineAzelastine may increase the anticoagulant activities of Indobufen.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Indobufen.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Indobufen.Approved, Investigational
BatroxobinIndobufen may increase the anticoagulant activities of Batroxobin.Experimental
BecaplerminIndobufen may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Indobufen is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololIndobufen may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinIndobufen may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BemiparinIndobufen may increase the anticoagulant activities of Bemiparin.Approved, Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Indobufen.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Indobufen is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Indobufen.Approved
BenorilateThe risk or severity of adverse effects can be increased when Indobufen is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Indobufen.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Indobufen is combined with Benzydamine.Approved
BeraprostBeraprost may increase the anticoagulant activities of Indobufen.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Indobufen is combined with Betamethasone.Approved, Vet Approved
BetaxololIndobufen may decrease the antihypertensive activities of Betaxolol.Approved
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Indobufen.Approved, Investigational
BevantololIndobufen may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Indobufen is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Indobufen.Approved, Investigational
BisoprololIndobufen may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinIndobufen may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololIndobufen may decrease the antihypertensive activities of Bopindolol.Approved
BrinaseIndobufen may increase the anticoagulant activities of Brinase.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Indobufen.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Indobufen.Investigational
BucindololIndobufen may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Indobufen is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Indobufen is combined with Bufexamac.Experimental
BuflomedilBuflomedil may increase the anticoagulant activities of Indobufen.Experimental
BufuralolIndobufen may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Indobufen is combined with Bumadizone.Experimental
BumetanideIndobufen may decrease the diuretic activities of Bumetanide.Approved
BupranololIndobufen may decrease the antihypertensive activities of Bupranolol.Approved
ButylphthalideButylphthalide may increase the anticoagulant activities of Indobufen.Investigational
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Indobufen.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Indobufen.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Indobufen.Experimental
CangrelorCangrelor may increase the anticoagulant activities of Indobufen.Approved
CaplacizumabIndobufen may increase the anticoagulant activities of Caplacizumab.Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Indobufen.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Indobufen is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Indobufen.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Indobufen.Approved, Vet Approved, Withdrawn
CarteololIndobufen may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolIndobufen may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Indobufen.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Indobufen.Approved, Investigational
CeliprololIndobufen may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinIndobufen may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Indobufen.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Indobufen.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Indobufen.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Indobufen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Indobufen.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Indobufen is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Indobufen.Approved
CilostazolCilostazol may increase the anticoagulant activities of Indobufen.Approved
CinoxacinIndobufen may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
Citric AcidIndobufen may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Indobufen is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Indobufen is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Indobufen is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Indobufen is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Indobufen is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Indobufen.Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Indobufen.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Indobufen.Vet Approved
CloranololIndobufen may decrease the antihypertensive activities of Cloranolol.Experimental
CloricromenIndobufen may increase the anticoagulant activities of Cloricromen.Experimental
ClorindioneIndobufen may increase the anticoagulant activities of Clorindione.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Indobufen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Indobufen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Indobufen is combined with Collagenase clostridium histolyticum.Approved, Investigational
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Indobufen is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Indobufen is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Indobufen is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Indobufen.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Indobufen.Experimental
CyclosporineIndobufen may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateIndobufen may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinIndobufen may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidIndobufen may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanIndobufen may increase the anticoagulant activities of Darexaban.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Indobufen.Approved, Investigational
DaunorubicinIndobufen may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Indobufen is combined with Deferasirox.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Indobufen.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Indobufen is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Indobufen.Experimental
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Indobufen is combined with Deoxycholic Acid.Approved
DersalazineThe risk or severity of adverse effects can be increased when Dersalazine is combined with Indobufen.Investigational
DesirudinIndobufen may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Indobufen is combined with Desmopressin.Approved
DesmoteplaseIndobufen may increase the anticoagulant activities of Desmoteplase.Investigational
DesonideThe risk or severity of adverse effects can be increased when Indobufen is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Indobufen is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Indobufen is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Indobufen is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Indobufen is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Indobufen is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Indobufen.Approved, Investigational
DextranIndobufen may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Indobufen may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Indobufen may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Indobufen may increase the anticoagulant activities of Dextran 75.Approved
DibekacinIndobufen may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Indobufen.Approved, Vet Approved
DicoumarolIndobufen may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Indobufen is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Indobufen is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Indobufen.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Indobufen is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Indobufen is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Indobufen.Approved
DihydrostreptomycinIndobufen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Indobufen.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Indobufen.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Indobufen.Approved
DiphenadioneIndobufen may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleDipyridamole may increase the anticoagulant activities of Indobufen.Approved
DitazoleIndobufen may increase the anticoagulant activities of Ditazole.Approved, Withdrawn
DoxorubicinIndobufen may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneIndobufen may increase the hyperkalemic activities of Drospirenone.Approved
Drotrecogin alfaIndobufen may increase the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Indobufen.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Indobufen.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Indobufen.Investigational
Edetic AcidIndobufen may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanIndobufen may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Indobufen.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Indobufen.Approved
EnoxacinIndobufen may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinIndobufen may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Indobufen.Experimental
EpanololIndobufen may decrease the antihypertensive activities of Epanolol.Experimental
EpinastineEpinastine may increase the anticoagulant activities of Indobufen.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Indobufen.Approved
EpirubicinIndobufen may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneIndobufen may decrease the antihypertensive activities of Eplerenone.Approved
EplivanserinEplivanserin may increase the anticoagulant activities of Indobufen.Investigational
eplivanserineeplivanserine may increase the anticoagulant activities of Indobufen.Investigational
EpoprostenolEpoprostenol may increase the anticoagulant activities of Indobufen.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Indobufen.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Indobufen.Approved, Investigational
EquileninThe risk or severity of adverse effects can be increased when Indobufen is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Indobufen is combined with Equilin.Approved
EsmololIndobufen may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Indobufen is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Indobufen is combined with Estrone sulfate.Approved
Etacrynic acidIndobufen may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Indobufen.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Indobufen is combined with Ethenzamide.Experimental
Ethyl biscoumacetateIndobufen may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Indobufen is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Indobufen.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Indobufen.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Indobufen.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Indobufen.Approved, Investigational
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Indobufen.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Indobufen.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Indobufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Indobufen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Indobufen.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Indobufen is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Indobufen is combined with Feprazone.Experimental
Ferulic acidIndobufen may increase the anticoagulant activities of Ferulic acid.Experimental
FibrinolysinIndobufen may increase the anticoagulant activities of Fibrinolysin.Investigational
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Indobufen.Approved, Investigational
FleroxacinIndobufen may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Indobufen.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Indobufen is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Indobufen is combined with Fludrocortisone.Approved
FluindioneIndobufen may increase the anticoagulant activities of Fluindione.Investigational
FlumequineIndobufen may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Indobufen is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Indobufen is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Indobufen.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Indobufen is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Indobufen is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Indobufen is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Indobufen is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Indobufen is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Indobufen is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Indobufen is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Indobufen.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Indobufen is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Indobufen.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Indobufen is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Indobufen is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Indobufen.Approved, Nutraceutical, Vet Approved
FondaparinuxIndobufen may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumIndobufen may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Indobufen.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Indobufen is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Indobufen.Approved
FramycetinIndobufen may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideIndobufen may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateIndobufen may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinIndobufen may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinIndobufen may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Indobufen.Approved, Withdrawn
GemifloxacinIndobufen may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinIndobufen may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinIndobufen may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AIndobufen may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GlucosamineGlucosamine may increase the antiplatelet activities of Indobufen.Approved
GPX-150Indobufen may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinIndobufen may increase the neuroexcitatory activities of Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Indobufen is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Indobufen is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Indobufen is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Indobufen is combined with HE3286.Investigational
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Indobufen is combined with Hemoglobin crosfumaril.Experimental
HeparinIndobufen may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineIndobufen may increase the anticoagulant activities of Higenamine.Investigational
HydralazineIndobufen may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Indobufen.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Indobufen is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Indobufen.Approved, Investigational
HydroxytyrosolHydroxytyrosol may increase the anticoagulant activities of Indobufen.Investigational
Hygromycin BIndobufen may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Indobufen is combined with Ibandronate.Approved, Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Indobufen is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Indobufen.Approved
IbudilastIbudilast may increase the anticoagulant activities of Indobufen.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Indobufen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Indobufen.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Indobufen.Approved
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Indobufen.Approved, Nutraceutical
IdarubicinIndobufen may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxIndobufen may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Indobufen.Approved, Investigational, Withdrawn
IfetrobanIfetroban may increase the anticoagulant activities of Indobufen.Investigational
IloprostIloprost may increase the anticoagulant activities of Indobufen.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Indobufen.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Indobufen is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Indobufen.Approved
IndenololIndobufen may decrease the antihypertensive activities of Indenolol.Withdrawn
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Indobufen.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Indobufen.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Indobufen.Approved, Investigational
IsepamicinIndobufen may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Indobufen.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Indobufen is combined with Istaroxime.Investigational
KanamycinIndobufen may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Indobufen.Experimental
KetanserinKetanserin may increase the anticoagulant activities of Indobufen.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Indobufen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Indobufen.Approved
LabetalolIndobufen may decrease the antihypertensive activities of Labetalol.Approved
LandiololIndobufen may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Indobufen.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Indobufen.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Indobufen.Approved, Investigational
LepirudinIndobufen may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanIndobufen may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololIndobufen may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinIndobufen may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Indobufen.Approved, Investigational
LinsidomineLinsidomine may increase the anticoagulant activities of Indobufen.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Indobufen.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Indobufen.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Indobufen.Approved
LonazolacThe risk or severity of adverse effects can be increased when Indobufen is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Indobufen.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Indobufen.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Indobufen is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Indobufen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Indobufen.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Indobufen.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Indobufen.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Indobufen.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Indobufen.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Indobufen is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Indobufen.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Indobufen is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Indobufen.Approved
MelagatranIndobufen may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Indobufen is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Indobufen.Approved, Vet Approved
MepindololIndobufen may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Indobufen.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Indobufen.Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Indobufen.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Indobufen.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Indobufen is combined with Methyl salicylate.Approved, Vet Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Indobufen is combined with Methylprednisolone.Approved, Vet Approved
MetipranololIndobufen may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Indobufen.Approved
MetoprololIndobufen may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideIndobufen may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinIndobufen may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MilrinoneMilrinone may increase the anticoagulant activities of Indobufen.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Indobufen.Approved
MizoribineThe risk or severity of adverse effects can be increased when Indobufen is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Indobufen.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Indobufen is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Indobufen is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Indobufen.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Indobufen.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Indobufen.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Indobufen.Approved
NadololIndobufen may decrease the antihypertensive activities of Nadolol.Approved
NadroparinIndobufen may increase the anticoagulant activities of Nadroparin.Approved
NafamostatIndobufen may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Indobufen.Approved
NaftopidilNaftopidil may increase the anticoagulant activities of Indobufen.Investigational
Nalidixic AcidIndobufen may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Indobufen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Indobufen is combined with NCX 1022.Investigational
NeamineIndobufen may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololIndobufen may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinIndobufen may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinIndobufen may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Indobufen.Approved
NetilmicinIndobufen may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Indobufen is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Indobufen.Approved
NimesulideNimesulide may increase the anticoagulant activities of Indobufen.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Indobufen.Investigational
NorfloxacinIndobufen may increase the neuroexcitatory activities of Norfloxacin.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Indobufen is combined with Obinutuzumab.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Indobufen is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Indobufen.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Indobufen.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Indobufen.Approved
Omacetaxine mepesuccinateThe risk or severity of can be d when Indobufen is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Indobufen.Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Indobufen.Approved, Nutraceutical
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Indobufen.Vet Approved
OtamixabanIndobufen may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Indobufen.Approved
Oxolinic acidIndobufen may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololIndobufen may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Indobufen.Approved, Withdrawn
OzagrelIndobufen may increase the anticoagulant activities of Ozagrel.Investigational
PamidronateThe risk or severity of adverse effects can be increased when Indobufen is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Indobufen is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Indobufen.Approved
ParnaparinIndobufen may increase the anticoagulant activities of Parnaparin.Approved, Investigational
ParomomycinIndobufen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Indobufen is combined with Parthenolide.Investigational
PazufloxacinIndobufen may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinIndobufen may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololIndobufen may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateIndobufen may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Indobufen.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Indobufen.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Indobufen.Approved
PhenindioneIndobufen may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonIndobufen may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Indobufen.Approved, Vet Approved
PicotamideIndobufen may increase the anticoagulant activities of Picotamide.Experimental
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Indobufen.Approved, Investigational
PindololIndobufen may decrease the antihypertensive activities of Pindolol.Approved
Pipemidic acidIndobufen may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinIndobufen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideIndobufen may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Indobufen.Approved, Investigational
Piromidic acidIndobufen may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Indobufen.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Indobufen is combined with Pirprofen.Experimental
Platelet Activating FactorIndobufen may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinIndobufen may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinIndobufen may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Indobufen.Approved
PractololIndobufen may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Indobufen.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Indobufen is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Indobufen is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Indobufen is combined with Prasterone sulfate.Investigational
PrasugrelPrasugrel may increase the anticoagulant activities of Indobufen.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Indobufen is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Indobufen is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Indobufen is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Indobufen is combined with Pregnenolone.Experimental, Investigational
ProbenecidThe serum concentration of Indobufen can be increased when it is combined with Probenecid.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Indobufen is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Indobufen.Approved, Investigational
PropranololIndobufen may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Indobufen is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Indobufen is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Indobufen.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Indobufen.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Indobufen.Vet Approved
Protein CIndobufen may increase the anticoagulant activities of Protein C.Approved
Protein S humanIndobufen may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeIndobufen may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinIndobufen may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Indobufen.Investigational
PuromycinIndobufen may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Indobufen.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Indobufen.Approved
RamatrobanRamatroban may increase the anticoagulant activities of Indobufen.Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Indobufen.Approved
RelcovaptanRelcovaptan may increase the anticoagulant activities of Indobufen.Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Indobufen.Approved
ResveratrolResveratrol may increase the anticoagulant activities of Indobufen.Approved, Experimental, Investigational
ReteplaseIndobufen may increase the anticoagulant activities of Reteplase.Approved
ReviparinIndobufen may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinIndobufen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RidogrelRidogrel may increase the anticoagulant activities of Indobufen.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Indobufen is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Indobufen is combined with Risedronate.Approved, Investigational
RivaroxabanIndobufen may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Indobufen.Investigational, Withdrawn
RosiglitazoneIndobufen may increase the anticoagulant activities of Rosiglitazone.Approved, Investigational
RosoxacinIndobufen may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinIndobufen may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinIndobufen may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Indobufen.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Indobufen.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Indobufen.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Indobufen.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Indobufen.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Indobufen.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Indobufen.Approved
SarpogrelateSarpogrelate may increase the anticoagulant activities of Indobufen.Investigational
SaruplaseIndobufen may increase the anticoagulant activities of Saruplase.Experimental
SelexipagIndobufen may increase the anticoagulant activities of Selexipag.Approved
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Indobufen.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Indobufen.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Indobufen is combined with Serrapeptase.Investigational
SevofluraneSevoflurane may increase the anticoagulant activities of Indobufen.Approved, Vet Approved
SisomicinIndobufen may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinIndobufen may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Indobufen.Approved
SotalolIndobufen may decrease the antihypertensive activities of Sotalol.Approved
SP1049CIndobufen may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinIndobufen may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinIndobufen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Indobufen.Approved
SRT501SRT501 may increase the anticoagulant activities of Indobufen.Investigational
StreptokinaseIndobufen may increase the anticoagulant activities of Streptokinase.Approved, Investigational
StreptomycinIndobufen may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinIndobufen may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Indobufen.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Indobufen.Approved
SulodexideIndobufen may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Indobufen.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Indobufen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Indobufen is combined with Suxibuzone.Experimental
TacrolimusIndobufen may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Indobufen.Approved
TalinololIndobufen may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Indobufen.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Indobufen.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Indobufen.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Indobufen is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Indobufen is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Indobufen.Approved, Investigational
TemafloxacinIndobufen may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Indobufen.Experimental, Investigational
TenecteplaseIndobufen may increase the anticoagulant activities of Tenecteplase.Approved
TenidapThe risk or severity of adverse effects can be increased when Indobufen is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Indobufen is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Indobufen.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Indobufen.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Indobufen.Approved
TertatololIndobufen may decrease the antihypertensive activities of Tertatolol.Experimental
TesmilifeneTesmilifene may increase the anticoagulant activities of Indobufen.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Indobufen.Approved
TicagrelorIndobufen may increase the anticoagulant activities of Ticagrelor.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Indobufen.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Indobufen is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololIndobufen may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Indobufen is combined with Tinoridine.Investigational
TinzaparinIndobufen may increase the anticoagulant activities of Tinzaparin.Approved
TioclomarolIndobufen may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirTipranavir may increase the antiplatelet activities of Indobufen.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Indobufen.Approved
TixocortolThe risk or severity of adverse effects can be increased when Indobufen is combined with Tixocortol.Approved, Withdrawn
TobramycinIndobufen may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Indobufen.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Indobufen.Approved
TorasemideIndobufen may decrease the diuretic activities of Torasemide.Approved
TositumomabThe risk or severity of adverse effects can be increased when Indobufen is combined with Tositumomab.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Indobufen.Approved
TranilastTranilast may increase the anticoagulant activities of Indobufen.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Indobufen.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Indobufen.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Indobufen.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Indobufen is combined with Triamcinolone.Approved, Vet Approved
TriamtereneIndobufen may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Indobufen is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Indobufen.Approved, Vet Approved
TriflusalTriflusal may increase the anticoagulant activities of Indobufen.Approved, Investigational
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Indobufen.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Indobufen is combined with Trolamine salicylate.Approved
TrovafloxacinIndobufen may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinIndobufen may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Indobufen is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Indobufen.Approved, Investigational
UrokinaseIndobufen may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Indobufen.Investigational, Withdrawn
ValrubicinIndobufen may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Indobufen.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Indobufen.Approved
Vitamin EVitamin E may increase the antiplatelet activities of Indobufen.Approved, Nutraceutical, Vet Approved
VorapaxarVorapaxar may increase the anticoagulant activities of Indobufen.Approved
WarfarinIndobufen may increase the anticoagulant activities of Warfarin.Approved
XimelagatranIndobufen may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Indobufen.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Indobufen.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Indobufen.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Indobufen is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Indobufen.Withdrawn
Zoptarelin doxorubicinIndobufen may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinIndobufen may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
107641
PubChem Substance
347828770
ChemSpider
96823
ChEBI
135239
ChEMBL
CHEMBL1765292
ATC Codes
B01AC10 — Indobufen

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Unknown StatusSupportive CareHealthy Volunteers1
3CompletedPreventionNonvalvular Atrial Fibrillation1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0781 mg/mLALOGPS
logP3.04ALOGPS
logP3.31ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)3.83ChemAxon
pKa (Strongest Basic)-3.5ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area57.61 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity83.75 m3·mol-1ChemAxon
Polarizability32.14 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as isoindolones. These are aromatic polycyclic compounds that an isoindole bearing a ketone.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Isoindoles and derivatives
Sub Class
Isoindolines
Direct Parent
Isoindolones
Alternative Parents
Phenylpropanes / Isoindoles / Tertiary carboxylic acid amides / Lactams / Monocarboxylic acids and derivatives / Carboxylic acids / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides
show 2 more
Substituents
Isoindolone / Isoindole / Phenylpropane / Monocyclic benzene moiety / Benzenoid / Tertiary carboxylic acid amide / Carboxamide group / Lactam / Carboxylic acid derivative / Carboxylic acid
show 11 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 16:47 / Updated on December 01, 2017 16:31